Evidence map›Paper›PMID 27724887›Full record

Trial reportBMC cancer2016

Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.

David Propper, Keith Jones, D Alan Anthoney, Wasat Mansoor, Daniel Ford, Martin Eatock, Roshan Agarwal, Michiyasu Inatani, Tomohisa Saito, Masaichi Abe and 1 more

Open access · goldAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

David PropperCentre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, Lower Ground Floor, Old Anatomy Building, Charterhouse Square, London, UK, EC1M 6BQ. d.j.propper@qmul.ac.uk.
Keith JonesChugai Pharmaceuticals Europe Ltd. Turnham Green, London, W4 1NN, UK.
D Alan AnthoneySt James Institute of Oncology, University of Leeds & Leeds Teaching Hospitals Trust, Leeds, LS9 7TF, UK.
Wasat MansoorDepartment Medical Oncology, Christie Hospital, Wilmslow Road, Withington, Manchester, M20 4BX, UK.
Daniel FordCancer Research Clinical Trials Team, Old Clinical Investigations Building, City Hospital, Dudley Road, Birmingham, B18 7QH, UK.
Martin EatockNorthern Ireland Cancer Clinical Trials Unit, Belfast City Hospital, East Podium, C Floor, Belfast, BT9 7AB, UK.
Roshan AgarwalWest London Cancer Research Network, Coulter Suite, 1st Floor Mint Wing, St Mary's Hospital, Praed St, London, W2 1 NY, UK.
Michiyasu InataniChugai Pharmaceutical Co., Ltd, Nihonbashi Muromachi 2-1-1, Chuo-ku, Tokyo, 103-8324, Japan.
Tomohisa SaitoChugai Pharmaceutical Co., Ltd, Nihonbashi Muromachi 2-1-1, Chuo-ku, Tokyo, 103-8324, Japan.
Masaichi AbeChugai Pharmaceutical Co., Ltd, Nihonbashi Muromachi 2-1-1, Chuo-ku, Tokyo, 103-8324, Japan.
T R Jeffry EvansBeatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, G12 OYN, UK.
Beatson West of Scotland Cancer Centre · GBBelfast City Hospital · GBBirmingham City Hospital · GBLeeds Teaching Hospitals NHS Trust · GBQueen Mary University of London · GBSt Mary's Hospital · GBThe Christie Hospital · GB

Funding

Cancer Research UK 11650Cancer Research UK 12946Cancer Research UK 20409
6 · The paper itself

Abstract

backgroundTP300, a recently developed synthetic camptothecin analogue, is a highly selective topoisomerase I inhibitor. A phase I study showed good safety and tolerability. As camptothecins have proven active in oesophago-gastric adenocarcinomas, in this phase II study we assessed the efficacy and safety of TP300 in patients with gastric or gastro-oesophageal junction (GOJ) adenocarcinomas.

methodsEligible patients had metastatic or locally advanced gastric or Siewert Types II or III GOJ inoperable adenocarcinoma. Patients were chemotherapy naïve unless this had been administered in the perioperative setting. TP300 was administered as a 1-h intravenous infusion every 3 weeks (a cycle) for up to 6 cycles at a starting dose of 8 mg/m

resultsIn Stage I of the study 20 patients (14 males, 6 females), median age 67 years (range 40 - 82), performance status ECOG 0/1, with GC [14] or GOJ carcinoma [6] were enrolled. Of the 16 evaluable patients, 11 received the planned dose increase to 10 mg/m

conclusionsThis study of TP300 showed good drug tolerability but it failed to demonstrate sufficient efficacy as measured by radiological response.

trial registrationEU-CTR 2009-012097-12 2009-09-03.

Indexed as

AdenocarcinomaAgedAntineoplastic AgentsCombined Modality TherapyDipeptidesEsophageal NeoplasmsEsophagogastric JunctionFemaleHeterocyclic Compounds, 4 or More RingsHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm StagingStomach NeoplasmsTreatment OutcomeAntineoplastic AgentsDipeptidesHeterocyclic Compounds, 4 or More RingsTP 300Advanced Gastric or Gastro-oesophageal junction adenocarcinomaOesophago-gastric adenocarcinomaPharmacodynamicsPharmacokineticsPhase II studySafety profileSiewert Types II & IIITopoisomerase-I inhibitor

Identifiers

PMID27724887
PMCPMC5057500
OpenAlexW2531489294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.